Positive effect of evobrutinib in CNS remyelination models and lack of synergy with clemastine-A dose response study.

ABSTRACT:

Background

To recover normal functions, remyelination in multiple sclerosis is crucial. Although endogenous remyelination occurs, it is often insufficient, and finding molecules promoting repair of demyelinated lesions is needed.

Objectives

To compare the remyelination potential of evobrutinib, an inhibitor of Bruton's tyrosine kinase and clemastine, an antagonist of M1 muscarinic acetylcholine receptor.

Methods

Remyelination was investigated in lysolecithin demyelinated organotypic mouse cerebellar slices and a transgenic Xenopus model of inducible-demyelination.

Results

Evobrutinib (100 nM) and clemastine (200 nM) potentiated remyelination of mouse cerebellar slices by a factor of 2.9 and 1.76, respectively. In conditionally demyelinated Xenopus

SUBMITTER: Martin E 

PROVIDER: S-EPMC11930471 | biostudies-literature | 2025 Jan-Mar

REPOSITORIES: biostudies-literature